首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   12篇
  免费   7篇
  2022年   2篇
  2019年   1篇
  2018年   1篇
  2017年   3篇
  2015年   1篇
  2013年   2篇
  2011年   4篇
  2008年   2篇
  2007年   1篇
  2004年   1篇
  1997年   1篇
排序方式: 共有19条查询结果,搜索用时 15 毫秒
1.
目的:评价多模式磁共振指导下超时间窗静脉应用重组组织型纤溶酶原激活剂rt PA治疗急性缺血性卒中的疗效及安全性。方法:将68例急性脑梗塞患者分为rt PA静脉溶栓组A组、强化抗栓治疗组B组,各组按药物干预时间再分为4.5小时亚组及4.5-6小时亚组。A组给予rt PA静脉溶栓治疗和常规治疗,B组给予首剂氯吡格雷300毫克+阿司匹林100毫克和常规治疗。治疗前行急诊头多模式磁共振检查,治疗24小时后复查头CT,分别于治疗前后不同时间点进行NIHSS评分和3个月MRS评分,记录不良事件的发生情况。结果:A组两个亚组治疗后各时间点NIHSS评分均明显低于B组,且A组4.5小时亚组治疗后NIHSS评分低于其4.5-6小时亚组,A组3个月预后良好患者比例显著高于B组,差异均有统计学意义(P0.05)。A组症状性颅内出血的发生率高于B组。结论:多模式头磁共振指导下超时间窗rt PA静脉溶栓治疗安全有效,远期疗效优于强化抗栓治疗,但颅内症状性出血风险略高于强化抗栓治疗。  相似文献   
2.
摘要 目的:探讨西洛他唑在急性脑梗死患者重组人组织型纤溶酶原激活物(rt-PA)溶栓治疗后的作用及对血清血小板溶酶体膜蛋白(CD63)、α颗粒膜糖蛋白(CD62p)、血小板活化因子(PAF)的作用分析。方法:选择2020年2月至2022年2月我院接诊的90例急性脑梗死患者,按照随机数表法分为观察组及对照组,各45例。两组均接受rt-PA溶栓治疗,对照组溶栓后使用阿司匹林治疗,观察组在对照组基础上,联合西洛他唑治疗,均连续治疗14 d。比较两组临床疗效、血清CD62p、CD63、PAF、全血粘度、血浆粘度和红细胞比容(HCT)及美国国立卫生院卒中量表(NIHSS)评分、巴氏量表(Barthel指数)评分的变化及出血事件发生率。结果:观察组患者的临床疗效总有效率为91.11%,高于对照组的73.33%,有统计学意义(P<0.05);观察组血清CD62p、CD63、PAF均比对照组低,有统计学意义(P<0.05);观察组全血粘度、血浆粘度、HCT均比对照组低,有统计学意义(P<0.05);观察组的NIHSS评分均低于对照组,Barthel指数高于对照组,有统计学意义(P<0.05);两组出血事件总发生率比较,无统计学意义(P>0.05)。结论:西洛他唑在急性脑梗死患者rt-PA溶栓治疗后的作用明显,可有效降低血清CD62p、CD63、PAF的表达,改善血小板功能,安全性较好,值得临床推广。  相似文献   
3.
目的:探索SITSSICH风险评分预测中国急性脑梗死患者rt.PA静脉溶栓(时间窗为4.5h,rt.PA剂量0.9mg/kg体重)治疗后症状性颅内出血(SICH)风险的效果,为使用SITSSICH风险评分指导溶栓治疗积累临床经验。方法:对86名进行rt-PA静脉溶栓(剂量0.9mg/kg体重)的急性脑梗死患者,进行SITSSICH风险评分,并记录总分及风险水平分层结果,按总分0、1、2、3、4、5、6、7、8、≥9分,分为10组,再按风险水平低危、平均、中危、高危分为4组,记录各组患者溶栓后有颅内出血(包括SICH)的比例,各组间进行比较。结果:SITSSICH风险评分0.5分、6分、7分、8分、≥9分各组SICH的比例分别为0.0%、8.3%、10.0%、25%和50.0%,卡方检验得x2=64.38,P〈0.001(线性趋势检验),提示随着SITSSICH风险评分值的增加SICH的比例也在增加,存在统计学上的差异。SITSSICH风险评分风险水平低危及平均组的SICH比率为0%,中危、高危组的SICH比率分别11.5%,50%,卡方检验得xZ=-59.52,P〈0.001(线性趋势检验),提示SITSSICH风险水平越高,SICH的比例也越高,存在统计学上的差异。另外,将SITSSICH风险评分风险水平分层和出血类型做spearman等级相关分析,得到spearman相关系数0.422,P〈0.001;说明SITSSICH风险评分风险水平分层和S1CH呈正相关。结论:对于经标准的rt—PA静脉溶栓方案(时间窗为4.5h,rt-PA剂量0.9mg/kg体重)治疗中国急性脑梗死患者,SITSSICH风险评分分值的增加与SICH风险的增加呈正相关,SITSSICH风险评分是一个能够预测rt-PA静脉溶栓后sICH风险的简单易行的实用的I临床工具。  相似文献   
4.
对70例急性心肌梗塞行清栓酶静脉给药的溶栓效果分析   总被引:1,自引:0,他引:1  
曾自成  李秀兰 《蛇志》1997,9(1):10-14
用清栓酶静脉给药对70例急性心肌梗塞病人持续进行24h溶栓疗法,再通率为88.57%;发病6h内接受溶栓者,再通率为93.9%,发病12h~24h接受溶栓者,再通率为33.3%,二者有显著性差异(P<0.05);阐述了清栓酶溶栓的疗效机理,认为这是目前最理想的溶栓剂  相似文献   
5.
Thrombomodulin (TM) is a cofactor for thrombin-mediated activation of protein C and thrombin-activatable fibrinolysis inhibitor (TAFI) and thereby helps coordinate coagulation, anticoagulation, fibrinolysis, and inflammation. Platelet factor 4 (PF4), a platelet α-granule protein and a soluble cofactor for TM-dependent protein C activation, stimulates protein C activation in vitro and in vivo. In contrast to stimulation of protein C activation, PF4 is shown here to inhibit activation of TAFI by thrombin-TM. Consequences of inhibition of TAFI activation by PF4 included loss of TM-dependent prolongation of clot lysis times in hemophilia A plasma and loss of TM-stimulated conversion of bradykinin (BK) to des-Arg(9)-BK by TAFIa in normal plasma. Thus, PF4 modulates the substrate specificity of the thrombin-TM complex by selectively enhancing protein C activation while inhibiting TAFI activation, thereby preventing the generation of the antifibrinolytic and anti-inflammatory activities of TAFIa. To block the inhibitory effects of PF4 on TAFI activation, heparin derivatives were tested for their ability to retain high affinity binding to PF4 despite having greatly diminished anticoagulant activity. N-acetylated heparin (NAc-Hep) lacked detectable anticoagulant activity in activated partial thromboplastin time clotting assays but retained high affinity binding to PF4 and effectively reversed PF4 binding to immobilized TM. NAc-Hep permitted BK conversion to des-Arg(9)-BK by TAFIa in the presence of PF4. In a clot lysis assay on TM-expressing cells using hemophilia A plasma, NAc-Hep prevented PF4-mediated inhibition of TAFI activation and the antifibrinolytic functions of TAFIa. Accordingly, NAc-Hep or similar heparin derivatives might provide therapeutic benefits by diminishing bleeding complications in hemophilia A via restoration of TAFIa-mediated protection of clots against premature lysis.  相似文献   
6.
目的:评价经膝下(Below the Knee, BTK)途径导管直接溶栓(Catheter-Directed Thrombolysis, CDT)治疗混合型下肢深静脉血栓形成(Deep Vein Thrombosis, DVT)的安全性和有效性。方法:回顾性分析2013年1月至2017年10月于徐州市肿瘤医院介入科接受经BTK途径CDT治疗的38例急性混合型DVT患者临床资料,其中男性患者26例,女性患者12例,年龄54±11岁。结果:技术成功率为100%。经小隐静脉穿刺途径28例,小隐静脉切开途径4例,胫后静脉切开途径4例,胫后静脉穿刺途径2例。行CDT前,所有患者均接受临时可回收滤器置入,并于术后2周内取出。36名患者DVT血栓溶解成功(Ⅱ和Ⅲ级)。2名未获得血栓溶解成功的患者,从症状发生到CDT时间均大于10天。对13例患者(左侧10例,右侧3例)进行髂静脉球囊扩张和支架植入。围手术期出现切口渗血4例,切开部位麻木5例,没有新发肺栓塞和大出血发等主要并发症。平均随访时间为2年(1个月-4年),28例患者超过1.5年。2例患者由于未服用华法林而出现反复髂股DVT。随访期间通畅率和PTS率分别为81.6%(31/38)和31.6%(12/38)。结论:采用经BTK途径行CDT治疗混合型DVT是安全有效的,围手术期及随访期间结果满意,是一种值得推广的方法。  相似文献   
7.
目的:评价介入技术治疗急性和亚急性门静脉(portal vein,PV)及肠系膜上静脉(superior mesenterie vein, SMV)血栓形成的临床疗效。方法:对28例治疗急性和亚急性(发病一周至一月)的PV及SMV血栓患者进行介入治疗。按介入治疗途径不同分为下述两组:选择经颈静脉穿刺门静脉(transjugular intrahepatic portosystemic shunt , TIPS途径)置管溶栓(19例)和经皮穿肝内门脉(percutaneous transhepatic)置管溶栓治疗(9例)。结果:所有患者随访一周至三个月,其中治疗成功24例,临床症状明显改善,无严重并发症。经TIPS途径治疗的患者组中,16例随访显示大部分血栓被清除,门静脉系统有血流通过,临床症状缓解。3例SMV及PV恢复部分血流,但临床症状无明显改善。经皮穿肝内门脉直接置管溶栓治疗组中,6例患者的PV及SMV内血栓大部分清除,血流基本改善,2例患者PV及SMV血流部分好转,临床症状无明显改善,严重并发症1例(术后两天死于腹腔出血)。结论:经TIPS途径介入技术和经皮穿肝内门脉直接置管溶栓治疗是治疗急性和亚急性PV及SMV血栓形成的有效方法,前者的疗效及安全性均好于后者。  相似文献   
8.
Therapeutic applications of ultrasound predate its use in imaging. A range of biological effects can be induced by ultrasound, depending on the exposure levels used. At low levels, beneficial, reversible cellular effects may be produced, whereas at high intensities instantaneous cell death is sought. Therapy ultrasound can therefore be broadly divided into “low power” and “high power” applications. The “low power” group includes physiotherapy, fracture repair, sonophoresis, sonoporation and gene therapy, whereas the most common use of “high power” ultrasound in medicine is probably now high intensity focused ultrasound. Therapeutic effect through the intensity spectrum is obtained by both thermal and non-thermal interaction mechanisms. At low intensities, acoustic streaming is likely to be significant, but at higher levels, heating and acoustic cavitation will predominate. While useful therapeutic effects are now being demonstrated clinically, the mechanisms by which they occur are often not well understood.  相似文献   
9.
We have developed a novel micro-mixer using a biological molecular ATP motor. The micro-mixer was constructed from arrays of chromatophore-embedded δ-free F0F1-ATPases, where the δ-free F1 part acted as a rotator to mix solutions, and the F0 part was driven by light. Confocal microscope studies indicated that the micro-mixer did not touch directly on the fibrin labeled with FITC. The nanomechanical force generated by the motor induced drug movement in the solution and accelerated the fibrinolysis process. All results strongly suggest that the micro-mixers generated a nanomechanical force which accelerated the fibrinolysis process in the presence of lower concentrations of lumbrokinase.  相似文献   
10.
Two fibrinolytic enzymes (QK-1 and QK-2) purified from the supernatant of Bacillus subtilis QK02 culture broth had molecular masses of 42,000 Da and 28,000 Da, respectively. The first 20 amino acids of the N-terminal sequence are AQSVPYGISQ IKAPALHSQG. The deduced protein sequence and its restriction enzyme map of the enzyme QK-2 are different from those of other proteases. The enzyme QK-2 digested not only fibrin but also a subtilisin substrate, and PMSF inhibited its fibrinolytic and amidolytic activities completely; while QK-1 hydrolyzed fibrin and a plasmin substrate, and PMSF as well as aprotinin inhibited its fibrinolytic activity. These results indicated QK-1 was a plasmin-like serine protease and QK-2 a subtilisin family serine protease. Therefore, these enzymes were designated subtilisin QK. The sequence of a DNA fragment encoding subtilisin QK contained an open reading frame of 1149 base pairs encoding 106 amino acids for signal peptide and 257 amino acids for subtilisin QK, which is highly similar with that of a fibrinolytic enzyme, subtilisin NAT (identities 96.8%). Asp32, His64 and Ser221 in the amino acid sequence deduced from the QK gene are identical to the active site of nattokinase (NK) produced by B. subtilis natto.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号